Flumatinib

DB11904InvestigationalSmall molecule

Flumatinib has been used in trials studying the treatment of Myelogenous Leukemia, Chronic.

Mechanism: Pharmacologically active on Tyrosine-protein kinase ABL1
Curator reviewed
Formula / weight: C₂₉H₂₉F₃N₈O · 562.601 g/mol (avg)
Also known as: Flumbatinib
Code names: HH-GV678

Resolves to

Compound

Structure

InChIKeyBJCJYEYYYGBROF-UHFFFAOYSA-NSMILESCN1CCN(CC2=CC=C(C=C2C(F)(F)F)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)N=C2)CC1

Targets

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

27Drug interactionsStructured to mechanism, not free text

12Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Flumatinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.